| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on March 13, 2007
Accepted on May 24, 2007
Department of Histology & Medical Embryology, Department of Psychology, Section of Neuroscience, Department of Medical Pathophysiology, Istituto Pasteur-Fondazione Cenci Bolognetti, Sapienza University of Rome, Italy
* To whom correspondence should be addressed. E-mail: carla.boitani{at}uniroma1.it.
To investigate the physiological effects of mPHGPx overexpression during early male germ cell differentiation, we have generated transgenic mice bearing the rat mPhgpx coding sequence driven by the mouse Synaptonemal Complex Protein 1 promoter, allowing the transgene to be specifically activated in the testis from the zygotene to diplotene stages of the first meiotic division. Northern/western blotting and immunocytochemical analyses of endogenous mPHGPx expression during spermatogenesis showed a low enzyme level in middle-late pachytene spermatocytes, but not in earlier meiotic stages, and a significant increase in mPHGPx content in round spermatids. The histological and TUNEL analysis of transgenic testes revealed a number of spermatogenetic defects, including primary spermatocytes apoptosis, haploid cell loss and seminiferous epithelium disorganization. In line with these features, adult transgenic male mice also displayed a reduction in fertility. Results obtained in this study suggest that mPHGPx expression is tightly regulated in pachytene spermatocytes, any spatial-temporal increase in mPHGPx expression resulting in a damage to spermatogenesis and eventual loss of haploid cells. Present findings in the mouse may be of interest to human male fertility.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |